Most Clicked PCMA SmartBrief Stories

1. 5 states allow automatic biosimilar substitution

PCMA SmartBrief | May 18, 2015

Interchangeable biosimilars may be substituted for reference products without prior notification in Colorado, Georgia, Tennessee, Utah and Washington state, according to the Generic Pharmaceutical Association. Drug Store News (05/13)

2. DEA arrests 22 pharmacists, doctors in Rx abuse sting

PCMA SmartBrief | May 21, 2015

The Drug Enforcement Agency arrested 22 doctors and pharmacists in a prescription drug abuse investigation covering Alabama, Arkansas, Louisiana and Mississippi. A single pharmacist in Arkansas sold 93,000 hydrocodone pills for $500,000 using faked prescriptions, according to a federal prosecutor. Reuters (05/20) The New York Times (tiered subscription model) (05/20)

3. Survey: Specialty drugs should be dispensed through specialty pharmacies

PCMA SmartBrief | May 19, 2015

Specialists who prescribe specialty drugs do not believe that all drugstores are equally qualified to handle and dispense complex medications, a North Star Opinion Research survey of specialists in New York found. Employers should not be forced through "any willing pharmacy" laws to contract with drugstores ill-equipped to handle specialty drugs, PCMA President and CEO Mark Merritt said. American Pharmacy News (5/18)

4. CVS acquires Omnicare

PCMA SmartBrief | May 21, 2015

The Wall Street Journal (tiered subscription model) (05/21)

5. Drugstore profits and margins grew in 2013

PCMA SmartBrief | May 20, 2015

Independent and chain pharmacies posted gains in 2013 in gross profits and gross margins, and gross margins for drugstores have remained stable at 22% to 24% for the past decade, according to the Census Bureau's Annual Retail Trade Report. Drug Channels (05/19)

6. Compounding pharmacy to pay $200M for meningitis outbreak

PCMA SmartBrief | May 20, 2015

U.S. Bankruptcy Court Judge Henry Boroff has approved New England Compounding Center's reorganization plan, which includes a $200 million payout to creditors and victims of a 2012 meningitis outbreak. Reuters (05/19)

7. J&J: 10 pipeline drugs are potential blockbusters

PCMA SmartBrief | May 22, 2015

Johnson & Johnson will submit at least 10 new drugs for review by 2019 and seek more than 40 expanded approvals for existing treatments. Each of the 10 potential new drugs could earn at least $1 billion annually, according to the company, and they include investigational treatments for psoriasis, multiple myeloma and rheumatoid arthritis. Many were developed with partners or licensed from other drugmakers. The Wichita Eagle (Kan.) (05/20) The Wall Street Journal (tiered subscription model) (05/20)

8. Medicaid enrollment growth exceeds expectations

PCMA SmartBrief | May 18, 2015

Almost 1.4 million more people than initially predicted have enrolled in Medicaid in seven states since the Affordable Care Act's enactment. Critics of the law say the enrollment surge justifies their warnings that expanding Medicaid would be too expensive, and proponents say the additional spending is offset by health and economic gains. Politico (05/18)

9. Calif. insurance exchange caps specialty drug copayments

PCMA SmartBrief | May 22, 2015

The Covered California health insurance exchange has announced it will limit specialty drug copayments for most enrollees to $250 per month. An exchange official said premiums across all plans would increase by less than 1% as a result of the change. Bloomberg (05/21)

10. CMS continues to support demo projects for dual-eligibles

PCMA SmartBrief | May 18, 2015

Enrollment is low in state demonstration projects for managing the health and costs of care for people eligible for both Medicare and Medicaid, but CMS officials say the Financial Alignment Initiative is starting to show positive results. Modern Healthcare (tiered subscription model) (05/15)

Sign up for PCMA SmartBrief

Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more